CONTRIBUTING FACTORS FOR STROKE:

Similar documents
Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

The University of Mississippi School of Pharmacy

Update on Current Trends in Hypertension Management

Diabetes Mellitus: A Cardiovascular Disease

Diabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?

Statistical Fact Sheet Populations

BENEFIT STATUS PRODUCT STRENGTH DIN PRESCRIBER MFR

Established Risk Factors for Coronary Heart Disease (CHD)

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Cedars Sinai Diabetes. Michael A. Weber

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Diabetes and the Heart

CONTRIBUTING FACTORS FOR STROKE:

Carotid Artery Stenosis

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Welcome and Introduction

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Eliquis and plavix combination therapy

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

The Burden of the Diabetic Heart

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Supplementary Online Content

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

hypertension Head of prevention and control of CVD disease office Ministry of heath

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

LLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.

What s In the New Hypertension Guidelines?

Cardio-Protective Medication Bundle. Louis H. Carter II, PharmD.

Management of Cardiovascular Disease in Diabetes

Morbidity & Mortality from Chronic Kidney Disease

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

The Many Faces of T2DM in Long-term Care Facilities

Impact of Resting Heart Rate on Mortality, Disability and Cognitive Decline in Patients after Ischemic Stroke

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Perioperative Stroke for the General Anesthesiologist and Specialist

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines

Diabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

BENEFIT STATUS MFR PRODUCT STRENGTH DIN PRESCRIBER

How to Reduce CVD Complications in Diabetes?

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

egfr > 50 (n = 13,916)

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Steps Against Recurrent Stroke (STARS)

Online Appendix (JACC )

This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Diabetic Nephropathy. Objectives:

C-Reactive Protein and Your Heart

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

DEPARTMENT OF GENERAL MEDICINE WELCOMES

Glucose and CV disease

Investor Conference Call

Adult Diabetes Clinician Guide NOVEMBER 2017

CLINICAL OUTCOME Vs SURROGATE MARKER

Glucose Control: Does it lower CV risk?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Long-Term Care Updates

Steps Against Recurrent Stroke (STARS)

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?

Predicting and changing the future for people with CKD

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes

ACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Epidemiology and Prevention of Stroke

Ischemic Heart Disease Mortality, Morbidity and Risk Factors of Coronary Care Unit Patients

Hypertension Update Clinical Controversies Regarding Age and Race

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Blood Pressure Management in Acute Stroke. Bradley Molyneaux, M.D., Ph.D. Departments of Neurology & Critical Care Medicine University of Pittsburgh

Challenges in Perioperative Medication Management. Learning Objectives. Case 1. » Appropriate use of beta-blockers. Management of diabetes drugs

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

The TNT Trial Is It Time to Shift Our Goals in Clinical

American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Supplement materials:

The American Diabetes Association estimates

Atrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

Antihypertensive Drugs Prescribing Pattern in Patients Attending to Medicine Outpatient Department

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

The 2002 National Health and Nutrition Examination

The prevalence of type 2 diabetes mellitus (diabetes) in

Cardiovascular Diseases and Diabetes

The New Diabetes Standard of Care: More Than Just Glycemic Control. Copyright

CV Risk Management in Diabetes Mellitus

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Invokana (canagliflozin) NEW INDICATION REVIEW

Transcription:

CONTRIBUTING FACTORS FOR STROKE: DIABETES AND OBESITY Fruzsina K. Johnson, MD Professor of Preclinical Sciences William Carey University College of Osteopathic Medicine

LEARNING OBJECTIVES The learner will be able to discuss the impact of obesity on the risk of cerebrovascular disease and stroke. The learner will be able to discuss the impact of diabetes on the risk of cerebrovascular disease and stroke. The learner will be familiar with current recommendations and guidelines regarding the management of obesity and diabetes as risk factors for stroke.

DIABETES

DIABETES INCLUDING ESTIMATED UNDIAGNOSED CASES

FROM 1980 THROUGH 2011, THE NUMBER OF AMERICANS WITH DIABETES HAS MORE THAN TRIPLED, FROM 5.6 MILLION TO 20.9 MILLION

PROJECTED INCREASE IN DIABETES BURDEN

PREDIABETES ALSO INCREASES THE RISK OF STROKE

PREDIABETES

OBESITY AND TYPE 2 DIABETES

OBESITY AND TYPE 2 DIABETES

METABOLIC SYNDROME INCREASES RISK OF ATHEROSCLEROSIS AND CVD Caplan, Louis R. Caplan's Stroke: A Clinical Approach. 5 th edition. Cambridge University Press 2016; Chapter 18: Stroke prevention

METABOLIC SYNDROME GREATLY INCREASES THE RISK OF CVD

DIABETES MELLITUS IS A MAJOR RISK FACTOR FOR STROKE The risk of stroke is increased by 1.5 3 fold for patients with diabetes Diabetes also doubles the risk of stroke recurrence Stroke outcomes are significantly worse among patients with diabetes including: increased hospital and long-term stroke mortality: at 1 year, mortality was twofold higher in people with diabetes compared with those without it after 5 years, only one-fifth of patients with diabetes survive. more residual neurological, functional disability longer hospital stays increases the risk of stroke-related dementia by more than threefold Idris, I., Thomson, G.A., Sharma, J.C. Diabetes mellitus and stroke. Review. Int J Clin Pract, January 2006, 60, 1, 48 56.

DIABETES CHANGES CLINICAL PRESENTATION OF STROKE Idris, I., Thomson, G.A., Sharma, J.C. Diabetes mellitus and stroke. Review. Int J Clin Pract, January 2006, 60, 1, 48 56.

RISK FACTORS FOR STROKE FATALITY IN DIABETIC PATIENTS Idris, I., Thomson, G.A., Sharma, J.C. Diabetes mellitus and stroke. Review. Int J Clin Pract, January 2006, 60, 1, 48 56.

CLINICAL TRIALS RELATING TO STROKE IN DIABETES Idris, I., Thomson, G.A., Sharma, J.C. Diabetes mellitus and stroke. Review. Int J Clin Pract, January 2006, 60, 1, 48 56.

RECOMMENDATIONS FOR STROKE PREVENTION IN DIABETES Idris, I., Thomson, G.A., Sharma, J.C. Diabetes mellitus and stroke. Review. Int J Clin Pract, January 2006, 60, 1, 48 56.

DIABETES AND CARDIOVASCULAR DISEASE

STROKE IS A MAJOR COMPLICATION OF DIABETES

1) STROKE IS SECOND ONLY TO ACUTE MYOCARDIAL INFARCTION (MI) AMONG DIABETES-RELATED COMPLICATIONS 2) IMPROVED GLYCEMIC CONTROL DECREASES THE RATE OF STROKE AND OTHER COMPLICATIONS

AMERICAN DIABETES ASSOCIATION RECOMMENDATIONS FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETES Glycemic control note: tight control has not been shown to confer greater protection, but can increase stroke risk by promoting hypoglycemia Note: recent studies suggest that sulfonylureas may increase ischemic stroke damage by inhibiting KATP channels in nerve and glia cells that are important for neuroprotection during ischemia Blood pressure control in diabetic patients angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) should be first line of therapy confer renoprotection Lipid control Antiplatelet agents For details see: http://professional.diabetes.org/content/clinicalpractice-recommendations American Diabetes Association. Cardiovascular disease and risk management. Sec. 9. In Standards of Medical Care in Diabetes 2017. Diabetes Care 2017;40(Suppl. 1): S75 S87

REFERENCES/RESOURCES 1. Caplan, Louis R. Caplan's Stroke: A Clinical Approach. 5 th edition. Cambridge University Press 2016; Chapter 18: Stroke prevention. 2. American Diabetes Association website: http://professional.diabetes.org/slidelibrary 3. Idris, I., Thomson, G.A., Sharma, J.C. Diabetes mellitus and stroke. Review. Int J Clin Pract, January 2006, 60, 1, 48 56. 4. American Diabetes Association. Standards of Medical Care in Diabetes 2017. Diabetes Care 2017;40(Suppl. 1) full text available for free at: http://care.diabetesjournals.org/content/40/supplement_1 5. Riu L., at al: Cerebrovascular Safety of Sulfonylureas: The Role of K ATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes. Diabetes 2016 Sep; 65(9): 2795-2809. Full text available for free at: http://diabetes.diabetesjournals.org/content/65/9/2795